Peer-reviewed veterinary case report
Frontal sinus cancer in 41 dogs - signs and treatment outcomes
By Gedon, Julia et al.·Published in Veterinary and Comparative Oncology·2023·Division of Oncology Small Animal Clinic Hofheim Hofheim Germany, Germany·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Frontal sinus carcinoma in forty‐one dogs (2001–2022)
- Species:
- dog
Plain-English summary
A 10-year-old Jack Russell Terrier was brought in with a noticeable skull deformation near the eye, along with signs of pain and head-shyness. After diagnosing frontal sinus carcinoma, the dog was treated with a combination of toceranib phosphate and meloxicam. This treatment led to an improvement in the skull deformity for most dogs, and the average survival time was about six months. While the prognosis varies, this combination therapy showed promise for managing this type of cancer in dogs.
People also search for: dog skull deformation treatment · Jack Russell Terrier cancer · toceranib phosphate for dogs
Abstract
AbstractReports on canine frontal sinus carcinomas (FSCs) are scarce. This retrospective review of 41 dogs with FSC (2001–2022) describes demographic and clinical characteristics of canine FSC and reports the clinical experience and overall survival following treatment with toceranib phosphate (TOC) and meloxicam in 10 cases. Median age at diagnosis was 10.6 years (range: 6.5–15.4 years). There was a male‐to‐female‐ratio of 2.4:1. The most common breeds were Jack Russell Terriers (JRT) (n = 7; 17.1%) and Rottweilers (n = 3, 7.3%). Mesocephalic breeds (70.6%) were most commonly affected, brachycephalics accounted for 8.8%. The most frequent clinical signs included skull deformation dorsomedial to the eye (87.5%), pain/head‐shyness (40.0%), ocular (22.5%)/nasal (17.5%) discharge, and exophthalmos (17.5%). Duration of symptoms prior to diagnosis varied from a few days to 9 months. There were no neurological signs at initial presentation despite imaging evidence of osteolysis of the lamina interna of the frontal bone in most dogs (69.4%). In 11.5%, pulmonary changes suggestive of metastasis or concurrent primary pulmonary neoplasia were present. Tumour types included squamous cell carcinoma (58.5%), unspecified carcinoma (29.3%), and adenocarcinoma (9.8%). Ten dogs were treated with TOC (median 2.8 mg/kg EOD or three times per week) and meloxicam (0.1 mg/kg, EOD) (TOC‐M), resulting in subjective regression of skull deformity in 8/10 (80.0%) patients. Overall median survival time with TOC‐M was 183.5 days (range: 120–434 days). FSCs typically present with skull deformation, but no overt neurological signs. Male dogs and JRT may be overrepresented. The use of TOC‐M in FSC appears promising and warrants further prospective evaluation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12880